SENSUS is intended for use as a transcutaneous electrical nerve stimulator for the symptomatic relief and management of chronic intractable pain, according to the company.
“This product has attracted attention among health care providers because of its potential benefit to patients suffering from chronic pain,” said Shai N. Gozani MD, PhD, president and CEO of NeuroMetrix, in the release. “FDA clearance keeps us on track to launch the SENSUS pain management system in the fourth quarter of 2012. We are particularly enthusiastic about adoption of the device by diabetes focused clinicians because a number of recent systematic literature reviews and meta-analyses have concluded that transcutaneous electrical nerve stimulation may be an effective and safe treatment for painful diabetic neuropathy.”
NeuroMetrix is headquartered in Waltham, Mass.
Related Articles on FDA Clearances:
Actuated Medical Receives FDA Clearance for Tubeclear System
Reflectance Medical Receives FDA Clearance for Oximeter
Proteus Digital Health Receives FDA Clearance for Ingestible Sensor
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.